Last updated 2026-07-26
TL;DR
DSIP (delta sleep-inducing peptide) was identified from rabbit brain blood in 1977 and studied in small human trials through the 1980s-90s, mostly in insomnia and stress contexts. Results were mixed and sample sizes tiny (often under 20 people). It is not FDA-approved for anything, and most of what's cited as "DSIP does X" is actually rat or rabbit data, not human evidence.
what is DSIP and where did it come from?
DSIP stands for delta sleep-inducing peptide, a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by Swiss researcher Schoenenberger and colleagues from the venous blood of rabbits during electrically induced sleep [1]. The name comes from the original hypothesis: that this peptide, found circulating during slow-wave (delta) sleep in rabbits, might be a natural sleep-promoting substance transferable between animals. That's the whole origin story, and it's worth sitting with for a second. The peptide is named for what researchers hoped it did in a rabbit model, not for a confirmed mechanism in humans. Fifty years later, we still don't have a clean, agreed-upon answer for what DSIP's actual receptor or binding target is in the human body. Some papers describe it as having actions on the hypothalamic-pituitary axis; others frame it more as a stress-response modulator than a sleep hormone per se [2]. DSIP is not a supplement or a drug approved for any indication. It's a research peptide with a research history that runs mostly from the late 1970s through the mid 1990s, then goes fairly quiet, with a smaller wave of renewed interest since the 2010s in preclinical and mechanistic work.
does DSIP actually improve sleep in humans?
The honest answer is: the human evidence is thin, old, and mixed, not a clean yes. A few small clinical studies from the 1980s tested DSIP in people with insomnia or stress-linked sleep problems, and the results were inconsistent rather than uniformly positive. One frequently cited trial, published in the early 1980s in patients with psychophysiological insomnia, reported some improvement in sleep quality and reduced nighttime awakenings with repeated DSIP administration, but the study population was small (under 20 subjects) and the effect was not dramatic or consistent across all sleep parameters measured [3]. Other trials from the same era found DSIP had little or no effect on standard polysomnographic measures like total sleep time or sleep latency, despite the peptide's name implying a direct delta-wave-boosting effect [4]. A 1985 review in a peptide research journal summed up the field's frustration bluntly: results across labs and species were inconsistent enough that DSIP's actual role in sleep regulation remained unresolved even after a decade of study [2]. That's not a modern skeptic talking. That's from researchers working with the peptide directly, in the 1980s, saying the data didn't line up cleanly. No large, modern, placebo-controlled human trial of DSIP for insomnia exists. What you're left with is a handful of small studies, mostly pre-1990, with mixed outcomes and no replication at scale. If someone tells you DSIP is a proven human sleep aid, they're overstating what the record shows. For a plain-language walkthrough of the dosing patterns used in those old trials and what modern users report, see DSIP dosage.
was DSIP tested for stress and the HPA axis, more than sleep?
Yes, and arguably this is where more of the research attention actually went. Several studies from the 1980s and 90s looked at DSIP's effects on the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-hormone system, rather than sleep architecture specifically. The working hypothesis in a lot of this literature is that DSIP might act as a kind of stress-buffering or homeostatic peptide, blunting excessive cortisol/ACTH responses rather than directly forcing sleep onset [2] [5]. Animal studies (rats, rabbits) showed DSIP could modulate corticotropin-releasing hormone and ACTH release under stress conditions. That's an animal finding, not a demonstrated human clinical effect, and it's frequently blurred together with the sleep claims in modern marketing copy. A small number of human studies looked at DSIP in conditions like alcohol withdrawal and opioid withdrawal, again with the stress-axis angle in mind, reporting some symptom improvements in very small samples [6]. These are interesting as historical data points. They are not evidence that DSIP treats withdrawal or normalizes cortisol in a general population, because the trials were small, uncontrolled by modern standards, and never followed up with larger confirmatory work.
is most of the DSIP research done in animals, not people?
Yes, and this is probably the single most important framing point for anyone reading DSIP research today. The bulk of mechanistic and dose-response data on DSIP comes from rodent and rabbit studies, not human trials [1] [2] [7]. That matters because a lot of what circulates online as "DSIP does X" is a rat finding, restated without the species label, until it reads like an established human fact. A finding like "DSIP reduced stress-induced corticosterone in rats" is real and citable. It is not the same claim as "DSIP reduces stress hormones in people," even though the two sentences get flattened into each other constantly in supplement marketing. When you're evaluating any claim about DSIP, the first question worth asking is simple: was this measured in a human, and if so, how many humans, and when? If the answer traces back to a rabbit study from 1978 or a rat study from the 1990s, treat the human claim as unproven, not confirmed.
is DSIP approved by the FDA or any regulator?
No. DSIP has no FDA approval for any indication, and it is not marketed legally in the United States as a drug or dietary supplement for human use. It falls into the same regulatory gray zone as many other "research peptides": sold by some vendors labeled "not for human consumption," used off-label by individuals, with no FDA-reviewed safety or efficacy data behind it. The FDA has taken broader action against unapproved compounded and research-use peptides sold as though they were approved therapeutics, and peptides in this general category have shown up on FDA's bulk drug substances review lists for compounding, without inclusion on the approved list. That's a regulatory status point, not a safety verdict either way, but it means nobody should assume DSIP has passed the kind of review a prescription sleep medication has. If you're weighing DSIP against a regulatory-approved option, it helps to know upfront: there's no FDA-approved DSIP product, no established human dose, and no long-term human safety database. Anything sold as DSIP in the U.S. right now is a research chemical, not an approved medicine.
how was DSIP typically dosed in the old clinical studies?
In the human trials from the 1980s, DSIP was generally given by intravenous or intramuscular injection, not orally, because peptides of this size are broken down in the gut before absorption. Doses in the insomnia and stress-related trials commonly ranged in the range of roughly 0.1 to 0.25 mg per administration, often given in the evening before sleep, sometimes repeated over several nights or weeks [3] [4]. These studies were not standardized the way a modern Phase II trial would be. Different labs used different doses, different injection schedules, and different outcome measures, which is part of why the literature reads as inconsistent rather than a clean dose-response curve. There is no FDA-reviewed or consensus human dosing protocol for DSIP today. Anyone researching modern self-administration practices, injection sites, or how people are running DSIP now should treat that as a separate question from the old clinical literature; the two aren't directly comparable. For the mechanics people actually discuss today, see how to take DSIP peptide, DSIP injection sites, and DSIP dosage.
what side effects showed up in the human studies?
The small clinical trials from the 1980s and 90s reported relatively few acute adverse effects at the doses tested, but 'relatively few in a 20-person trial from 1983' is a very different safety standard than a modern reviewed drug label. Reported issues in some of the older literature include mild reactions at the injection site, occasional headache, and transient changes in blood pressure in a subset of subjects [3] [4]. There is no large, modern pharmacovigilance dataset for DSIP. No systematic long-term safety study exists in the way it would for an approved sleep medication. That absence of reported problems in tiny old trials should not be read as "DSIP is proven safe." It mostly means nobody has looked hard enough, in a large enough population, for long enough, to know. Anyone considering DSIP should read the side effect picture as unresolved, not reassuring. For a fuller rundown of what's reported and what's simply unknown, see DSIP peptide side effects.
why does the human evidence stop being current after the 1990s?
Interest in DSIP as a clinical sleep drug candidate largely faded after the 1980s and early 90s, likely for the reason most peptide sleep candidates fade: the human results weren't compelling enough, relative to existing sleep drugs, to justify the cost of large trials. Benzodiazepines and later Z-drugs (zolpidem, zaleplon, eszopiclone) dominated the insomnia drug market through the 1990s and 2000s, backed by large controlled trials DSIP never had. There's been a smaller resurgence of DSIP mentions in preclinical and mechanistic literature since roughly the 2010s, often in the context of stress physiology, oxidative stress, or as a comparator peptide in animal studies, rather than as an active human insomnia drug candidate [7]. That's real ongoing science, but it's not the same as a company running new Phase II human sleep trials. So if you search for "DSIP clinical trial" expecting a current NIH-registered study for insomnia, you likely won't find one active. The clinical trial trail on ClinicalTrials.gov for DSIP as a sleep therapeutic is sparse and old-registry material rather than an active modern pipeline .
does DSIP work differently from melatonin or prescription sleep drugs?
| First described | 1977, rabbit blood [1] | Human circadian studies, 1950s-90s | 1980s-90s | |
|---|---|---|---|---|
| FDA approval status | None | OTC supplement; some prescription formulations approved | Approved prescription drugs | |
| Human trial base | Handful of small trials, <20 subjects typical | Large, ongoing | Large, ongoing | |
| Route in studies | IV/IM injection | Oral | Oral | |
| Modern active trials | Sparse/inactive | Active | Active (post-market studies) | The table isn't meant to declare a winner. It's meant to show the size and recency gap in the evidence, which is the part marketing pages tend to skip. |
Mechanistically, yes, at least on paper, though the human confirmation is much weaker for DSIP. Melatonin works on MT1/MT2 receptors tied to circadian timing, and it has a large modern human trial base, including FDA-reviewed prescription formulations for specific indications. Z-drugs and benzodiazepines act on GABA-A receptor complexes, with decades of large randomized trials behind their approvals. DSIP's proposed mechanism is different and much less pinned down: some researchers frame it as acting through hypothalamic and stress-axis pathways rather than the classic GABAergic sleep circuit, but this is based mostly on animal data, and the actual human receptor pharmacology for DSIP has never been clearly established in the literature [2]. | | DSIP | Melatonin | Z-drugs (e.g. zolpidem) |
what does 'DSIP is a research peptide' actually mean in practice?
It means DSIP is sold, where it's sold at all, as a chemical for laboratory or research use, not as an approved human drug or supplement, and buying it puts the legal and safety responsibility on the individual, not a regulator. This is standard language across the research-chemical peptide market and applies to plenty of peptides beyond DSIP. In practical terms, that means: no FDA-reviewed manufacturing standard guarantees purity or dose accuracy, no product insert lists confirmed human side effects, and no agency is tracking adverse events tied to DSIP use the way MedWatch tracks approved drugs. Quality varies a lot by supplier, which is why sourcing matters more with a compound like this than it would with a pharmacy-dispensed, FDA-approved medication. If you do decide to research DSIP further, the sourcing question (who's actually behind the product, and what pharmacy fulfills it) matters as much as the dosing question. DSIP Peptide reviews provider options against that backdrop rather than presenting DSIP as a settled, proven sleep therapy; that distinction, between 'available for research' and 'proven for sleep,' is the one worth holding onto.
what's the honest bottom line on what DSIP actually does?
Based on the published record: DSIP is a peptide identified in rabbit blood in 1977, studied in a handful of small human trials through the 1980s and into the 90s for insomnia and stress-related conditions, with mixed and inconsistent results, and it is not FDA-approved for any human use today [1] [2] [3] [4]. The strongest, most repeatable finding in the literature is not "DSIP fixes insomnia." It's closer to "DSIP has some effect on stress-hormone regulation and possibly on subjective sleep quality in small samples, but the effect is inconsistent across studies and hasn't been confirmed in a large modern trial" [2] [5]. That's a much more modest and more honest claim than the name of the peptide implies. If you're researching DSIP because you want a proven human sleep drug, the current literature doesn't get you there. If you're researching it as a historically interesting, mechanistically unresolved peptide with a real but thin human data trail, that's an accurate way to frame it. Cycle length, dosing, and injection practices discussed elsewhere on this site (see DSIP cycle length) describe how people are using it today; they are not a substitute for the missing large-scale human efficacy trial.
Frequently asked questions
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide, a nine-amino-acid peptide first isolated from rabbit blood in 1977 by Swiss researchers studying electrically induced sleep [1]. The name reflects the original hypothesis that it promotes deep, slow-wave (delta) sleep, though human confirmation of that effect has been inconsistent across the small trials that followed.
Does DSIP actually make you sleep better?
The human data is mixed, not conclusive. Small 1980s trials in insomnia patients reported some improvement in sleep quality with DSIP, while others found little effect on measured sleep parameters like total sleep time or latency [3][4]. No large modern controlled trial has confirmed a reliable sleep benefit in humans.
Is DSIP FDA approved?
No. DSIP has no FDA approval for any human indication and is not a legally marketed drug or supplement in the U.S. [8]. It's sold, where available, as a research-use chemical, meaning there's no FDA-reviewed purity, dosing, or safety standard behind it.
Is the DSIP research done in humans or animals?
Most of it is animal research. The original 1977 discovery came from rabbit blood, and much of the mechanistic work on stress hormones and the HPA axis has been done in rats and rabbits [1][2][7]. Human trials exist but are small (often under 20 subjects) and mostly from the 1980s-90s.
How was DSIP dosed in the old human studies?
Clinical studies from the 1980s typically gave DSIP by IV or IM injection, in doses roughly around 0.1 to 0.25 mg per administration, often before sleep [3][4]. There was no standardized protocol across labs, and no FDA-reviewed dosing guideline exists today.
What are the known side effects of DSIP?
Older small trials reported mostly mild issues like injection site reactions, occasional headache, and transient blood pressure changes in a subset of subjects [3][4]. There's no large modern safety database, so the honest answer is that DSIP's full side effect profile in humans is unresolved, not reassuring or well-established either way.
Does DSIP reduce stress or cortisol in humans?
There's a real research thread on DSIP and the HPA (stress hormone) axis, but most of the strongest findings, like modulating ACTH and corticosterone release, come from rat and rabbit studies, not confirmed human trials [2][5]. Small human studies exist in contexts like withdrawal symptoms, with limited sample sizes.
Is DSIP the same as melatonin?
No. Melatonin acts on MT1/MT2 circadian receptors and has decades of large human trials and some FDA-reviewed formulations behind it. DSIP's mechanism is far less established in humans, based mostly on animal stress-axis research, with a much smaller and older human trial base [1][2].
Are there active clinical trials on DSIP today?
No large, active modern trial program for DSIP as a sleep therapeutic appears in the public trial registry; what exists is sparse and tied to older registry entries rather than a current pipeline [9]. Most current DSIP-related publications are preclinical or mechanistic, not new human efficacy trials.
Why did DSIP research slow down after the 1980s?
Interest faded largely because the human trial results were inconsistent and small-scale compared to established sleep drugs like benzodiazepines and later Z-drugs, which had large controlled trials behind their approvals. DSIP never generated the kind of compelling, replicated human efficacy data needed to justify large-scale drug development.
Can DSIP be taken orally?
The clinical studies that exist used injection (IV or IM), not oral dosing, because peptides this size are generally degraded in the digestive tract before meaningful absorption [3][4]. There's no established or studied oral human dosing protocol for DSIP in the published literature.
Is DSIP legal to buy in the United States?
It's sold by some suppliers as a research chemical labeled not for human consumption, occupying a regulatory gray zone rather than being an approved or banned substance outright. It has no FDA approval for human use, so anyone acquiring it is doing so outside any FDA-reviewed drug or supplement framework [8].
Sources
- Schoenenberger & Monnier, original DSIP isolation research summarized in peptide literature: DSIP was first isolated from rabbit venous blood during electrically induced sleep, described in 1977 research
- Graf & Kastin, 'Delta-sleep-inducing peptide: a review', Neuroscience & Biobehavioral Reviews: Review noting inconsistent findings on DSIP's role in sleep and stress regulation across studies
- Schneider-Helmert, clinical study of DSIP in insomnia patients: Small clinical trial reporting mixed sleep quality effects of DSIP in insomnia patients
- Studies on DSIP and polysomnographic sleep parameters: Trial reporting limited effect of DSIP on measured sleep parameters like sleep latency and total sleep time
- Research on DSIP and HPA axis / stress hormone modulation: DSIP studied for effects on stress hormone (ACTH/corticosterone) regulation
- DSIP studied in withdrawal symptom contexts: Small human studies examined DSIP in alcohol/opioid withdrawal symptom contexts
- Preclinical/mechanistic DSIP research, stress physiology literature: Modern preclinical research continues to study DSIP mechanisms mostly in animal models